Health Canada has authorized the sale of Arepanrix™ H1N1 vaccine based on no conclusive clinical testing. The authorization is based on the Health Canada review of available data on the quality, safety and immunogenicity of similar vaccines, which established the benefit/risk profile in favour of inoculating the Canadian population.
Read the Notice of Decision issued by Health Canada. The decision by the Health Minister was based on a belief (not qualified or informed) that immediate action is required to deal with the H1N1 risk. The assertion that the decision is based on limited clinical testing is being misapplied. There has been NO conclusive results from any clinical trials on the Arepanrix H1N1 vaccine.
This report is designed to inform you how the risks outweigh the benefits of the vaccine. It will demonstrate how the Health Canada assessment is flawed and contradictory to established research on the detrimental health effects of the vaccine ingredients contained in Arepanrix.
Read more...
No comments:
Post a Comment
Thanks for your comment it is much appreciated.